ArticleMMWR. Morbidity and mortality weekly report2018
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.
Article in MMWR. Morbidity and mortality weekly report, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- Epidemiological trends and determinants of mumps outbreaks: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Use of M-M-R II outside of the routinely recommended age range - a systematic literature review.Human vaccines & immunotherapeutics · 2022Pooled it
- Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.MMWR. Morbidity and mortality weekly report · 2022Guideline
- Recurrent Mumps in a Fully Vaccinated Young Adult With a Prior Breakthrough Infection: A Case Report.Cureus · 2026Article
- Mumps Vaccination Policies and Epidemiological Consequences: A Comparative Review of the United States and Japan.Epidemiologia (Basel, Switzerland) · 2026Review
- Serological Mumps Evaluation of Medical Students in Catalonia (Spain): Is a Third Dose of Vaccine Needed?Journal of medical virology · 2026Article
- A study on knowledge, attitude and practices (KAP) towards adult immunizations among health care professionals.Journal of family medicine and primary care · 2026Article
- The effect of mumps vaccine on the incidence of mumps in Hefei: An interrupted time-series analysis.Human vaccines & immunotherapeutics · 2025Article
- Evaluation and optimization of mumps-containing vaccination strategies: a study based on an individual-based stochastic model.EClinicalMedicine · 2025Article
- Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study.Human vaccines & immunotherapeutics · 2025Article
- Article
- Review
- Mumps Encephalitis in a Measles Rubella (MR)-Vaccinated Child: A Rare but Preventable Complication.Cureus · 2025Article
- Patterns of Decline in Measles, Mumps, and Rubella Neutralizing Antibodies and Protection Levels Through 10 Years After a Second and Third Dose of MMR Vaccine.Open forum infectious diseases · 2025Article
- Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination.The Lancet regional health. Southeast Asia · 2025Article
- Structure-based design of glycoprotein subunit vaccines for mumps.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Modeling the population-level impact of a third dose of MMR vaccine on a mumps outbreak at the University of Iowa.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study.Vaccines · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A substantial increase in the number of mumps outbreaks and outbreak-associated cases has occurred in the United States since late 2015 (1,2). To address this public health problem, the Advisory Committee on Immunization Practices (ACIP) reviewed the available evidence and determined that a third dose of measles, mumps, rubella (MMR) vaccine is safe and effective at preventing mumps. During its October 2017 meeting, ACIP recommended a third dose of a mumps virus-containing vaccine* for persons previously vaccinated with 2 doses who are identified by public health authorities as being part of a group or population at increased risk for acquiring mumps because of an outbreak. The purpose of the recommendation is to improve protection of persons in outbreak settings against mumps disease and mumps-related complications. This recommendation supplements the existing ACIP recommendations for mumps vaccination (3).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.